酒精性肝病诊断现状

doi:10.3969/j.issn.1672-5069.2014.01.003

Abstract

Li Liangping. Diagnosis of alcoholic liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 9-11.

[1] Asrani SK,Kamath PS,Pedersen R,et al. Liver related mortality in the US is underestimated. Hepatology,2010,52：408A.
[2] 历有名,陈卫星,虞朝辉,等. 浙江省酒精性肝病流行病学调查慨况. 中华肝脏病杂志,2003,1：647-649.
[3] 黄顺玲,戴水奇,张雪红,等. 湖南省酒精性肝病流行病学调查慨况. 中国医师杂志,2005,7：426-427.
[4] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南. 中华肝脏病杂志,2010,18（3）：163-166.
[5] European Association for the Study of Liver.EASL clinical practical guidelines：management of alcoholic liver disease.J Hepatol,2012,57（2）：399-420.
[6] Chalasani N,Younossi Z,Lavine JE,et al. The diagnosis and management of non-alcoholic fatty liver disease：practice guideline by the American Association for the Study of Liver Diseases,American College of Gastroenterology,and the American Gastroenterological Association. Hepatology,2012,55（6）：2005-2023.
[7] Dunn W,Sanyal AJ,Brunt EM,et a1.Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease. J Hepatol,2012,57（2）：387-391.
[8] Rehm J,Taylor B,Mohapatra S,et al.Alcohol as a risk factor for liver cirrhosis：a systematic review and meta-analysis. Drug Alcohol Rev,2010,29（4）：437-445.
[9] O’Shea RS,Dasarathy S,McCullough AJ. Alcoholic liver disease. Practice Guideline Committee of the American Association for the Study of Liver Diseases;Practice Parameters Committee of the American College of Gastroenterology. Hepatology,2010,51（1）：307-328.
[10] Piano SM,Rosi S,Cavallin M,et al. Urinary ethyl glucuronide improves the detection of alcohol consumption in liver transplant candidates and recipients. Hepatology,2012,56：977A.
[11] Stewart SH,Koch DG,Burgess DM,et al. Sensitivity and specificity of urinary ethyl glucuronide and ethyl sulfate in liver disease patients.Alcohol Clin Exp Res,2013,37（1）：150-155.
[12] Staufer K,Andresen H,Vettorazzi E,et al. Urinary ethyl glucuronide as a novel screening tool in patients pre- and post-liver transplantation improves detection of alcohol consumption. Hepatology,2011,54（5）：1640-1649.
[13] Lucey MR,Mathurin P,Morgan TR. Alcoholic hepatitis. N Engl J Med,2009,360：2758-2769.
[14] Singal AK,Shah VH. Alcoholic hepatitis：prognostic models and treatment. Gastroenterol Clin N Am,2011,40：611-639.
[15] Dunn W,Angulo P,Sanderson S,et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology,2006,131（4）：1057-1063.
[16] Singal1 A,Kamath1 PS,Gores GJ,et al. Alcoholic hepatitis： Current challenges and future directions. Clin Gastroenterol Hepatol,2013,doi:10.1016/j.cgh.2013.06.013. [Epub ahead of print]
[17] Dunn W,Jamil LH,Brown LS,et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology,2005,41（2）：353-358.
[18] Louvet A,Naveau S,Abdelnour M,et al. The Lille model：a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology,2007,45（6）：1348-1354.
[19] Singal AK,Kuo YF,Anand BS. Hepatitis C virus infection in alcoholic hepatitis：prevalence patterns and impact on in-hospital mortality. Eur J Gastroenterol Hepatol,2012,24（10）：1178-1184.

Diagnosis of alcoholic liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[4]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[5]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[6]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[7]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[8]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[9]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[10]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[11]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.
[12]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[13]	Yan Xisheng, Li Wei, Wang Jian, et al. Changes of serum cytokines and intestinal flora distribution in patients with alcoholic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 518-521.
[14]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[15]	Zhang Junfei, Xu Heming, Song Haiyan, et al. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome:poor diagnostic sensitivity of Paris' criteria in Chinese patients [J]. Journal of Practical Hepatology, 2019, 22(4): 537-540.